FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2751-2752 June 28, 2007 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

To the Editor: The treatment of patients with the steroid-resistant nephrotic syndrome (SRNS) is challenging. Persistent proteinuria and hypoalbuminemia result in serious complications and progressive kidney disease. Intensive treatment regimens show varying results in inducing remission but are associated with adverse effects. On the basis of suggestions that B lymphocytes are crucial in the pathogenesis of the nephrotic syndrome,¹ we examined the efficacy of treatment with rituximab, a monoclonal antibody against CD20 antigen, in patients with SRNS that was resistant to treatment with high-dose corticosteroids, alkylating agents, and calcineurin inhibitors.

Five patients (three with initial resistance and two with late . . . [Full Text of this Article]

This article has been cited by other articles:

• Ahmed, M. S., Wong, C. F. (2008). Rituximab and nephrotic syndrome: a new therapeutic hope?. Nephrol Dial Transplant 23: 11-17 [Full Text]  
• Yang, T., Nast, C. C., Vo, A., Jordan, S. C. (2008). Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol Dial Transplant 23: 377-380 [Full Text]